azd3427
Small moleculeexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 17, 2020 (NCT04630067)
Timeline
Indications
Mechanism of action
- Relaxin receptor 1INHIBITOR
RXFP1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06611423 | Phase 1 | Oct 15, 2024 | AstraZeneca, Clinical Trial Consultants AB, Karolinska Institute |
| NCT05737940 | Phase 2 | Apr 24, 2023 | AstraZeneca, Parexel |
| NCT04890548 | Phase 1 | Nov 23, 2021 | AstraZeneca, Parexel |
| NCT04630067 | Phase 1 | Nov 17, 2020 | AstraZeneca, Henry Ford Health System, Parexel |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 4 | 4 | 2 | 2020 |
| Parexel | For profit | 3 | 0 | 2 | 2020 |
| Clinical Trial Consultants AB | For profit | 1 | 0 | 1 | 2024 |
| Henry Ford Health System | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Karolinska Institute | Academic/Hospital | 1 | 0 | 1 | 2024 |
5 organizations
Page 1 / 1